Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07017179 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

This is a Multi-centre, Multi-drug, Platform Study in Chinese Participants Living With Obesity / Overweight

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 2 months later Aug 6, 2026 → Oct 23, 2026
See other at-risk trials from AstraZeneca

Record History

  1. Primary and study completion pushed from Aug 6, 2026 to Oct 23, 2026 Enrollment increased: 14 → 16 participants · Eligibility criteria expanded, about 14 words Show 2 more changesShow less
    • Enrollment increased: 14 → 16 participants
    • Eligibility criteria expanded, about 14 words
  2. Enrollment reduced: 871 → 14 participants Trial status changed: Recruiting → Active, Not Recruiting · Site details revised at 3 of 3 sitesv8 Show 2 more changesShow less
    • Trial status changed: Recruiting → Active, Not Recruiting
    • Site details revised at 3 of 3 sites
  3. Site details revised at 1 of 3 sitesv7
  4. 2 versions Re-verified since Dec 17, 2025, no change to tracked fieldsv5-v6
  5. Study Identification, Study Statusv4
Show 2 earlier versionsHide 2 earlier versions
  1. Primary endpoints: 1 to 2 Interventions: AZD6234 (Drug), Placebo (Drug) to AZD6234 (Drug), AZD6234 in combination with AZD9550 (Drug), AZD9550 (Drug), Placebo (Drug), Placebo (Drug), Plocebo (Drug) · Eligibility criteria expanded, about 56 words · Secondary endpoints: 7 to 18 · 2 morev3 Show 5 more changesShow less
    • Interventions: AZD6234 (Drug), Placebo (Drug) to AZD6234 (Drug), AZD6234 in combination with AZD9550 (Drug), AZD9550 (Drug), Placebo (Drug), Placebo (Drug), Plocebo (Drug)
    • Eligibility criteria expanded, about 56 words
    • Secondary endpoints: 7 to 18
    • Study description expanded, about 65 words
    • Study arms: 2 to 6

    See this version in full on ClinicalTrials.gov ↗

  2. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
AstraZeneca
727 trials monitored
See 61 trials at risk
Obesity
3,560 trials monitored
See 142 trials at risk
This study is to assess the safety and tolerability, PK characterisation, efficacy, and immunogenicity of the study intervention, and it allows assessment of the monotherapy or combination therapy of AZD6234 and AZD9550 in different sub-studies.
Trial Details
NCT Number NCT07017179
Lead Sponsor AstraZeneca
Conditions Obesity/Overweight
Enrollment 16 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov